首页> 外文OA文献 >Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio 2.0 and Average HER2 Copy Number ≥4.0 and 6.0

【2h】

Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio 2.0 and Average HER2 Copy Number ≥4.0 and 6.0

机译：2018年美国临床肿瘤学会/美国病理学家学院的影响HER2指南对乳腺癌患者2指南的准则更新，具有等离异性的HER2免疫组化结果，重点关注HER2 / CEP17比例<2.0和平均HER2拷贝数≥4.0和<6.0

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Raza S. Hoda; Edi Brogi; Jin Xu; Katia Ventura; Dara S. Ross; Chau Dang; Mark Robson; Larry Norton; Monica Morrow; Hannah Y. Wen;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio = 4.0 and < 6.0 [J] . Hoda Raza S., Brogi Edi, Xu Jin, Archives of pathology & laboratory medicine . 2020,第5期

机译：2018年美国临床肿瘤学会/美国病理学家学院的影响HER2指南对乳腺癌两种乳腺癌评估的准则更新，具有较大的HER2免疫组化结果，重点关注HER2 / CEP17比率= 4.0和<6.0
2. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers [J] . Singh Kamaljeet, Tantravahi Umadevi, Lomme Michele M., Breast cancer research and treatment. . 2016,第3期

机译：更新的2013年美国病理学家学院/美国临床肿瘤学会（CAP / ASCO）对人表皮生长因子受体2（HER2）荧光原位杂交（FISH）检测的指南建议增加了HER2阳性和HER2模棱两可的乳腺癌病例; 836例浸润性乳腺癌HER2 FISH结果的回顾性研究
3. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization [J] . Bethune Gillian C., van Zanten Daniel Veldhuijzen, MacIntosh Rebecca F., Histopathology: Official Journal of the British Division of the International Academy of Pathology . 2015,第6期

机译：2013年美国临床肿瘤学会/美国病理学家学院的影响有关浸润性乳腺癌的人类表皮生长因子受体2（HER2）检测的指南建议：重点关注被荧光原位评估为HER2基因扩增的'明确'肿瘤杂交
4. Automatization of HER2 Status Assessment in Breast Cancer [C] . Denis Makhov, Andrey Samorodov, Elena Slavnova Ural Symposium on Biomedical Engineering, Radioelectronics and Information Technology . 2019

机译：乳腺癌中HER2状态评估的自动化
5. Analysis of the oncogenic cooperation between mutp53 and HER2 to propose mutp53 as a biomarker for HER2-positive breast cancer. [D] . Russo, Amanda Deanna. 2014

机译：分析mutp53和HER2之间的致癌合作，提出mutp53作为HER2阳性乳腺癌的生物标志物。
6. Guideline Summary: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor HER2 Testing in Breast Cancer [O] . 2007

机译：指南摘要：美国临床肿瘤学会/美国病理学家学院关于乳腺癌中人表皮生长因子受体HER2检测的指南建议
7. Changes in identification of Her2 status according to 2018 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing: A real-world study based on consecutive hospital cohort of patients with Her2 IHC 2+ in China (2007-2017) [O] . Ying Xu, Changjun Wang, Yi-Dong Zhou, 2019

机译：根据2018年美国病理学家/美国临床肿瘤学会（CAP / ASCO）指南，人表皮生长因子受体2（HER2）荧光原位杂交（鱼类）测试的指南建议：真实世界研究基于中国连续医院患者的中国2+患者（2007-2017）

Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio 2.0 and Average HER2 Copy Number ≥4.0 and 6.0

著录项

引文网络

相似文献

相关主题

期刊订阅